BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Remura bromfenac: Phase III data

Top-line data from the double-blind, placebo-controlled, U.S. Phase III WEST trial in 420 patients with dry eye disease showed that both doses of Remura missed the co-primary endpoints of significantly improving one sign and one symptom of dry eye disease at day 42 vs. placebo. Both doses of Remura significantly improved one sign and one symptom from baseline to 42 days (p<0.0001 for both), which...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >